Skip to main content
Article thumbnail
Location of Repository

A phase II study of bortezomib in patients with MALT lymphoma

By Marlene Troch, Constanze Jonak, Leonhard Müllauer, Andreas Püspök, Michael Formanek, Wolfgang Hauff, Christoph C. Zielinski, Andreas Chott and Markus Raderer

Abstract

The activity of bortezomib in patients with MALT lymphoma is unclear. This study shows that that bortezomib is active in patients with MALT lymphoma. However, an unexpectedly high rate of toxicities was seen, warranting assessment of combination schedules with bortezomib at a lower dose than given in this study

Topics: Brief Reports
Publisher: Ferrata Storti Foundation
OAI identifier: oai:pubmedcentral.nih.gov:2675689
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles


    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.